SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 前列腺癌是男性中最常见的癌症。最近有两项研究表明，摄入维生素E和硒可能会预防前列腺癌。SELECT的目标是比较硒、维生素E、硒加维生素E和安慰剂对前列腺癌发生的影响(好的和坏的)。次要目标是确定这些补充剂对肺癌和结直肠癌以及所有其他癌症的影响。在全国范围内，将有3.24万名男性参与这项研究。遴选将包括55岁及以上的男性(非裔美国男性可能50岁及以上)，目标是在登记的人中有20%是少数族裔。维克森林大学医学院临床中心将在五年内招募250名男性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prostrate cancer is the most common cancer diagnosed among men. Recently two studies have suggested that vitamin E and selenium intake may prevent prostate cancer. The goal of SELECT is to compare the effects (good and bad) of selenium, vitamin E, selenium plus vitamin E and placebo on the occurrence of prostate cancer. Secondary goals are to determine the effects of these supplements on the occurrence of lung and colorectal cancer and all other cancers combined. Nationwide there will be 32,400 men taking part in the study. SELECT will include men aged 55 and older (African American men my be 50 years of age and older), with a goal of 20% of those enrolled being minorites. The Wake Forest University School of Medicine clinical center will recruit 250 men over five years.